Showing 5221-5240 of 8875 for: Cochrane Systematic Reviews Back
- Music therapy for end-of-life care
Cochrane Systematic Reviews, 10-Jun-2019
Music therapy in end-of-life care aims to improve a person's quality of life by helping relieve symptoms, addressing psychological needs, offering support, facilitating communication, and meeting spiritual needs. In addition, music therapists assist famil
- Music therapy for people with schizophrenia and schizophrenia‐like disorders
Cochrane Systematic Reviews, 29-May-2017
Music therapy is a therapeutic approach that uses musical interaction as a means of communication and expression. Within the area of serious mental disorders, the aim of the therapy is to help people improve their emotional and relational competencies, an
- Music therapy for people with substance use disorders
Cochrane Systematic Reviews, 9-May-2022
Substance use disorder (SUD) is the continued use of one or more psychoactive substances, including alcohol, despite negative effects on health, functioning, and social relations. Problematic drug use has increased by 10% globally since 2013, and harmful
- Music‐based therapeutic interventions for people with dementia
Cochrane Systematic Reviews, 23-Jul-2018
Dementia is a clinical syndrome with a number of different causes which is characterised by deterioration in cognitive, behavioural, social and emotional functions. Pharmacological interventions are available but have limited effect to treat many of the s
- MVA85A vaccine to enhance BCG for preventing tuberculosis
Cochrane Systematic Reviews, 30-Apr-2019
Tuberculosis causes more deaths than any other infectious disease globally. Bacillus Calmette-Guérin (BCG) is the only available vaccine, but protection is incomplete and variable. The modified Vaccinia Ankara virus expressing antigen 85A (MVA85A) is a vi
- Mycobacterium vaccae immunotherapy for treating tuberculosis
Cochrane Systematic Reviews, 20-Jan-2003
Some authorities have advocated Mycobacterium vaccae immunotherapy for treating tuberculosis and other infections caused by mycobacteria.
- Mycophenolate mofetil for relapsing-remitting multiple sclerosis
Cochrane Systematic Reviews, 6-Feb-2014
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system and a leading cause of disability in young and middle-aged adults. Mycophenolate mofetil (MMF) is an immunosuppressive agent that has been used for the prevention of allog
- Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation
Cochrane Systematic Reviews, 21-Jul-2014
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is associated with improved outcomes for people with various hematologic diseases; however, the morbidity and mortality resulting from acute and subsequently chronic graft-versus-host disease (
- Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients
Cochrane Systematic Reviews, 26-Nov-2015
Modern immunosuppressive regimens after kidney transplantation usually use a combination of two or three agents of different classes to prevent rejection and maintain graft function. Most frequently, calcineurin-inhibitors (CNI) are combined with corticos
- Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea
Cochrane Systematic Reviews, 3-Nov-2020
Obstructive sleep apnoea (OSA) is a syndrome characterised by episodes of apnoea (complete cessation of breathing) or hypopnoea (insufficient breathing) during sleep. Classical symptoms of the disease — such as snoring, unsatisfactory rest and daytime sle
- N‐acetylcarnosine (NAC) drops for age‐related cataract
Cochrane Systematic Reviews, 28-Feb-2017
Cataract is the leading cause of world blindness. The only available treatment for cataract is surgery. Surgery requires highly-trained individuals with expensive operating facilities. Where these are not available, patients go untreated. A form of treatm
- N‐acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication
Cochrane Systematic Reviews, 12-Feb-2019
Helicobacter pylori (H pylori) is one of the most common pathogens to establish and cause infection in human beings, affecting about 50% of the world's population. Prevalence may be as high as 83% in Latin American countries and as low as 17% in North Ame
- N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure
Cochrane Systematic Reviews, 9-Dec-2020
Acute liver failure is a rare and serious disease. Acute liver failure may be paracetamol-induced or non-paracetamol-induced. Acute liver failure not caused by paracetamol (acetaminophen) has a poor prognosis with limited treatment options. N-acetylcystei
- N‐acetylcysteine for sepsis and systemic inflammatory response in adults
Cochrane Systematic Reviews, 12-Sep-2012
Death is common in systemic inflammatory response syndrome (SIRS) or sepsis-induced multisystem organ failure and it has been thought that antioxidants such as N-acetylcysteine could be beneficial.
- Naftidrofuryl for acute stroke
Cochrane Systematic Reviews, 2-Sep-2008
Stroke is the third most common cause of death and the most common cause of disability in the western world. The development of drugs to limit the effects of brain damage caused by stroke continues but no routine effective treatment has yet been identifie
- Naftidrofuryl for dementia
Cochrane Systematic Reviews, 4-Nov-2011
Dementia is a brain disorder characterized by the permanent loss of higher cognitive functions. A number of vasodilatory drug treatments are prescribed for dementia. Naftidrofuryl is one such medicine which is reported to improve clinical symptoms signifi
- Naftidrofuryl for intermittent claudication
Cochrane Systematic Reviews, 12-Dec-2012
Lifestyle changes and cardiovascular prevention measures are a primary treatment for intermittent claudication (IC). Symptomatic treatment with vasoactive agents (Anatomic Therapeutic Chemical Classification (ATC) for medicines from the World Health Organ
- Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Cochrane Systematic Reviews, 11-Oct-2018
Benign prostatic hyperplasia (BPH) is a common condition in ageing men that may cause lower urinary tract symptoms (LUTS). Treatment aims are to relieve symptoms and prevent disease-related complications. Naftopidil is an alpha-blocker (AB) that has a hig
- Nalbuphine for postoperative pain treatment in children
Cochrane Systematic Reviews, 25-May-2016
Several surveys over the past few years have demonstrated that postoperative pain in children is not treated appropriately. One pharmacological treatment option in a multimodal approach for postoperative pain treatment is the systemic administration of op
- Naloxone for opioid‐exposed newborn infants
Cochrane Systematic Reviews, 12-Oct-2018
Naloxone, a specific opioid antagonist, is available for the treatment of newborn infants with cardiorespiratory or neurological depression that may be due to intrauterine exposure to opioid. It is unclear whether newborn infants may benefit from this the
